Cancer Imaging (Jul 2024)
Correction: Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation
- Nabeel Mansour,
- Kathrin Heinrich,
- Danmei Zhang,
- Michael Winkelmann,
- Maria Ingenerf,
- Lukas Gold,
- Konstantin Klambauer,
- Martina Rudelius,
- Frederick Klauschen,
- Michael von Bergwelt-Baildon,
- Jens Ricke,
- Volker Heinemann,
- C. Benedikt Westphalen,
- Wolfgang G. Kunz
Affiliations
- Nabeel Mansour
- Department of Radiology, University Hospital, LMU Munich
- Kathrin Heinrich
- Department of Medicine III, University Hospital, LMU Munich
- Danmei Zhang
- Department of Medicine III, University Hospital, LMU Munich
- Michael Winkelmann
- Department of Radiology, University Hospital, LMU Munich
- Maria Ingenerf
- Department of Radiology, University Hospital, LMU Munich
- Lukas Gold
- Department of Radiology, University Hospital, LMU Munich
- Konstantin Klambauer
- Department of Radiology, University Hospital, LMU Munich
- Martina Rudelius
- Institute of Pathology, Ludwig-Maximilians-Universität Munich
- Frederick Klauschen
- Institute of Pathology, Ludwig-Maximilians-Universität Munich
- Michael von Bergwelt-Baildon
- Department of Medicine III, University Hospital, LMU Munich
- Jens Ricke
- Department of Radiology, University Hospital, LMU Munich
- Volker Heinemann
- Department of Medicine III, University Hospital, LMU Munich
- C. Benedikt Westphalen
- Department of Medicine III, University Hospital, LMU Munich
- Wolfgang G. Kunz
- Department of Radiology, University Hospital, LMU Munich
- DOI
- https://doi.org/10.1186/s40644-024-00724-5
- Journal volume & issue
-
Vol. 24,
no. 1
pp. 1 – 1
Abstract
No abstracts available.
